Acrivon appoints Santhosh Palani, Ph.D., CFA, to board of directors effective March 4, 2024

Acrivon Therapeutics, Inc.

Dr. Palani appointed board member effective March 4, 2024; receives 32,500 share option grant vesting over 3 years.
He brings experience as former investment partner at PFM Health Sciences and prior roles at NEA, Cowen, Pfizer, Takeda.
No transactions requiring disclosure under Item 404(a); standard indemnification agreement entered.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Santhosh Palani, Ph.D., CFA

director

ACRV · Acrivon Therapeutics, Inc.

Effective: 2024-03-04
Filed: March 4, 2024, 6:59 PM ET

On March 1, 2024, the Board of Directors of Acrivon Therapeutics, Inc. (the “Company”) appointed Santhosh Palani, Ph.D., CFA, as a director of the Company, effective March 4, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Santhosh Palani, Ph.D., CFA was appointed as director at Acrivon Therapeutics, Inc..

Action: appointed
Role: director

Exact text from the filing

On March 1, 2024, the Board of Directors of Acrivon Therapeutics, Inc. (the “Company”) appointed Santhosh Palani, Ph.D., CFA, as a director of the Company, effective March 4, 2024.

View on SEC.gov

Acrivon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-056937

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.